AZD7762

Name: AZD7762
Brand: Selleck Chemicals
SKU: S1532
Rating: 5 (80 reviews)

For research use only.

Catalog No.S1532

80 publications

CAS No. 860352-01-8

AZD7762 is a potent and selective inhibitor of Chk1 with IC50 of 5 nM in a cell-free assay. It is equally potent against Chk2 and less potent against CAM, Yes, Fyn, Lyn, Hck and Lck. Phase 1.

Selleck's AZD7762 has been cited by 80 publications

Cancer Cell, 2019, 35(6):851-867

PubMed: 31185210 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Cancer Discov, 2012, 2(6):524-39

PubMed: 22628408 ( click the link to review the publication )

Nat Biotechnol, 2011, 29(6):542-6

PubMed: 21623355 ( click the link to review the publication )

Mol Cell, 2020, 22 pii: S1097-2765(20)30231-8

PubMed: 32353258 ( click the link to review the publication )

J Clin Invest, 2020, 139080

PubMed: 33016928 ( click the link to review the publication )

Nat Commun, 2020, 29;11(1):2086

PubMed: 32350249 ( click the link to review the publication )

Nucleic Acids Res, 2020, 48(17):9710-9723

PubMed: 32890395 ( click the link to review the publication )

Biomaterials, 2020, 248:120032

PubMed: 32304937 ( click the link to review the publication )

Cell Rep, 2020, 31(12):107800

PubMed: 32579927 ( click the link to review the publication )

Cell Rep, 2020, 12;31(6):107632

PubMed: 32402277 ( click the link to review the publication )

Cell Rep, 2020, 30(7):2416-2429

PubMed: 32075739 ( click the link to review the publication )

Haematologica, 2020, 105(3):784-795

PubMed: 31289205 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-1300-x

PubMed: 32335582 ( click the link to review the publication )

Cancers (Basel), 2020, 12(9)E2498

PubMed: 32899210 ( click the link to review the publication )

Cell Death Dis, 2020, 28;11(4):298

PubMed: 32345958 ( click the link to review the publication )

Radiat Environ Biophys, 2020,

PubMed: 32857208 ( click the link to review the publication )

Cancers (Basel), 2020, 12(7):1726

PubMed: 32610557 ( click the link to review the publication )

Life Sci Alliance, 2020, 3(8):e202000671

PubMed: 32571801 ( click the link to review the publication )

Nat Cell Biol, 2019, 21(6):778-790

PubMed: 31160710 ( click the link to review the publication )

J Thorac Oncol, 2019, 14(6):1032-1045

PubMed: 30771522 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(7):2290-2304

PubMed: 30538111 ( click the link to review the publication )
Cancers (Basel), 2019, 11(8)

PubMed: 31362447 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(4):762-770

PubMed: 30872379 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(8):1439-1450

PubMed: 31142662 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163.MCT-19-0474

PubMed: 31597711 ( click the link to review the publication )

Mol Cancer Res, 2019, 17(10):1985-1998

PubMed: 31300540 ( click the link to review the publication )

Cancer Cell Int, 2019, 19:195

PubMed: 31372095 ( click the link to review the publication )

Cell Cycle, 2019, 18(8):834-847

PubMed: 30943845 ( click the link to review the publication )

Br J Pharmacol, 2019, 10.1111/bph.14916

PubMed: 31670839 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163.MCT-19-0290

PubMed: 31871265 ( click the link to review the publication )

Oncotarget, 2019, 10(62):6691-6712

PubMed: 31803363 ( click the link to review the publication )

Nucleic Acids Res, 2018, 46(10):5029-5049

PubMed: 29596642 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(7):1629-1643

PubMed: 29326282 ( click the link to review the publication )

Cell Rep, 2018, 24(13):3393-3403.e5

PubMed: 30257201 ( click the link to review the publication )

Diabetes, 2018, 67(11):2319-2328

PubMed: 30104248 ( click the link to review the publication )

Cancer Lett, 2018, 431:142-149

PubMed: 29859297 ( click the link to review the publication )

Chem Res Toxicol, 2018, 31(7):612-618

PubMed: 29897742 ( click the link to review the publication )

Cancer Med, 2018, 7(8):3955-3964

PubMed: 29963769 ( click the link to review the publication )

Oncotarget, 2018, 9(71):33589-33600

PubMed: 30323901 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1392

PubMed: 29123096 ( click the link to review the publication )

Haematologica, 2017, 102(5):826-834

PubMed: 28154085 ( click the link to review the publication )

Cell Syst, 2017,

PubMed: 28017544 ( click the link to review the publication )

Cancer Lett, 2017, 392:71-82

PubMed: 28126323 ( click the link to review the publication )

J Exp Clin Cancer Res, 2017, 36(1):1

PubMed: 28049532 ( click the link to review the publication )

Eur J Pharm Sci, 2017, 109:223-232

PubMed: 28822757 ( click the link to review the publication )
Oncotarget, 2017, 8(7):10966-10979

PubMed: 28030798 ( click the link to review the publication )

Cancer Res, 2016, 76(11):3319-31

PubMed: 26988986 ( click the link to review the publication )

Oncogene, 2016, 35(36):4689-97

PubMed: 26804177 ( click the link to review the publication )

PLoS Pathog, 2016, 12(2):e1005424

PubMed: 26891221 ( click the link to review the publication )

Mol Cancer Res, 2016, 14(5):437-47

PubMed: 26979711 ( click the link to review the publication )

J Biol Chem, 2016, 291(17):9330-42

PubMed: 26940878 ( click the link to review the publication )

Anticancer Res, 2016, 36(6):2649-57

PubMed: 27272773 ( click the link to review the publication )

Oncotarget, 2016, 7(23):34688-702

PubMed: 27167194 ( click the link to review the publication )

Oncotarget, 2016, 7(14):18159-70

PubMed: 26921248 ( click the link to review the publication )

J Pathol, 2015, 10.1002/path.4528

PubMed: 25757065 ( click the link to review the publication )

Biochem Pharmacol, 2015, 93(2):210-20

PubMed: 25478729 ( click the link to review the publication )

Biochem Pharmacol, 2015, 93(2):210-20

PubMed: ( click the link to review the publication )

PLoS One, 2015, 10(6):e0129090

PubMed: 26046346 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 25544753 ( click the link to review the publication )

Oncotarget, 2015, 6(35):37229-40

PubMed: 26439697 ( click the link to review the publication )

Oncotarget, 2015, 6(25):21074-84

PubMed: 26025928 ( click the link to review the publication )

BMC Cancer, 2015, 15:462

PubMed: 26054341 ( click the link to review the publication )

Cell Rep, 2014, 10.1016/j.celrep.2014.10.024

PubMed: ( click the link to review the publication )

Cell Rep, 2014, 9(4):1375-86

PubMed: 25456132 ( click the link to review the publication )

Sci Signal, 2014, 7(326):ra47

PubMed: 24847116 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1223

PubMed: 24810059 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1253

PubMed: 24853431 ( click the link to review the publication )

Int J Oncol, 2014, 45(3):1159-66

PubMed: 24969815 ( click the link to review the publication )

PLoS One, 2014, 9(10):e111146

PubMed: 25343454 ( click the link to review the publication )
Int J Gynecol Cancer, 2014, 24(5):838-43

PubMed: 24804869 ( click the link to review the publication )

Oncotarget, 2014, 5(21):10546-57

PubMed: 25301733 ( click the link to review the publication )

Br J Cancer, 2013, 110(2):510-9

PubMed: 24327015 ( click the link to review the publication )

J Cell Mol Med, 2013, 18(1):143-55

PubMed: 24238094 ( click the link to review the publication )

PLoS One, 2013, 8(2):e55493

PubMed: 23405159 ( click the link to review the publication )

Cancer Biol Ther, 2012, 13(6):379-88

PubMed: 22313687 ( click the link to review the publication )

Cancer Biol Ther, 2011, 12(3):215-28

PubMed: 21642769 ( click the link to review the publication )

PLoS One, 2010, 5(12):e14335

PubMed: 21179472 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Chk Inhibitors

Biological Activity

Description

AZD7762 is a potent and selective inhibitor of Chk1 with IC50 of 5 nM in a cell-free assay. It is equally potent against Chk2 and less potent against CAM, Yes, Fyn, Lyn, Hck and Lck. Phase 1.

Targets

Chk1 ^[1] (Cell-free assay)	Chk2 ^[1] (Cell-free assay)
5 nM	<10 nM

In vitro

AZD7762, a more selective Chk1 inhibitor, inhibits Chk1 phosphorylation of a cdc25C peptide by reversibly binding to the ATP-binding site of Chk1, with IC50 of 5 nM and K_i of 3.6 nM. AZD7762 induces cell arrest with EC50 of 0.620 μM, and significantly abrogates the camptothecin induced G2 arrest with an EC50 of 10 nM, by blocking the chk1 dependent degradation of Cdc25A and activation of Cyclin A. AZD7762 (300 nM) enhances the antitumor efficacy of gemcitabine against SW620 and topotecan against MDA-MB-231 by reducing the GI50 values from 24.1 nM and 2.25 μM to 1.08 nM and 0.15 μM, respectively. ^[1] AZD7762 shows cytotoxicity against a variety of neuroblastoma cell lines bearing p53 wild type, p53 mutation, Mdm2 amplification or p14 deletion with IC50 values ranging from 82.6-505.9 nM. ^[2]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
KASUMI-1	M{nJ[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3TQVmlEPTB;MD6wNFAzOzRizszN	NVLoXohmW0GQR1XS
NKM-1	Ml7IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnP4TWM2OD1yLkCwNFQyPSEQvF2=	NXGxPFVsW0GQR1XS
MV-4-11	M13kN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXjLWHpyUUN3ME2wMlAxODR{NTFOwG0>	MnTtV2FPT0WU
NCI-H1703	NVjx[IZqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoH2TWM2OD1yLkCwOlQ{KM7:TR?=	NU\EZYN2W0GQR1XS
A204	NV7RclRbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mk[wTWM2OD1yLkCwPFU3KM7:TR?=	MnTOV2FPT0WU
CGTH-W-1	M3u4N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWrEPVVbUUN3ME2wMlAyPDJizszN	NU\LbGF6W0GQR1XS
MLMA	MkOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWr1XFRXUUN3ME2wMlAzQDR7IN88US=>	MYLTRW5ITVJ?
GOTO	M{fOdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlW5TWM2OD1yLkCzNVIh\|ryP	M2fjSHNCVkeHUh?=
KE-37	M{C5NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIrYUJRKSzVyPUCuNFMyPDJizszN	MY\TRW5ITVJ?
ES4	M4fTcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVTuNXk2UUN3ME2wMlA{OjVzIN88US=>	MlTMV2FPT0WU
ATN-1	NFnoepVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MknJTWM2OD1yLkCzOFE4KM7:TR?=	NF;rWo1USU6JRWK=
MHH-PREB-1	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHHVNolKSzVyPUCuNFM1PDJizszN	M2rWVnNCVkeHUh?=
SW756	M4f2dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFLvdZNKSzVyPUCuNFM2PzlizszN	MnL0V2FPT0WU
CTV-1	NYrVbHpYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXXJR\|UxRTBwMEO4PVYh\|ryP	M3jCS3NCVkeHUh?=
HCC1806	NWDQNGZwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUXJR\|UxRTBwMESwNlIh\|ryP	MkjEV2FPT0WU
NEC8	M3nXV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NILjcIZKSzVyPUCuNFQzODNizszN	NUf0Rm12W0GQR1XS
P12-ICHIKAWA	NXXsUXJRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFLjWYdKSzVyPUCuNFQ{OTZizszN	MYfTRW5ITVJ?
DEL	M2jWW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIfmUnJKSzVyPUCuNFQ2QTJizszN	NGrEN\|BUSU6JRWK=
KM12	NUXLO3E{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4X5e2lEPTB;MD6wOVE2QCEQvF2=	MYjTRW5ITVJ?
LB1047-RCC	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmnETWM2OD1yLkC2NFI2KM7:TR?=	MXLTRW5ITVJ?
LB2241-RCC	M1vBRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWPTcHVmUUN3ME2wMlA3OTB{IN88US=>	MljDV2FPT0WU
NOMO-1	NIfWcZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkDLTWM2OD1yLkC2NVE2KM7:TR?=	NEjwcGJUSU6JRWK=
NB14	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3\jb2lEPTB;MD6wOlE{PiEQvF2=	NUXhcm9IW0GQR1XS
ONS-76	NHniPItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NET2VVZKSzVyPUCuNFYyQTZizszN	NI[4NHhUSU6JRWK=
HD-MY-Z	NIL1fXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnPBTWM2OD1yLkC2NlU2KM7:TR?=	M1HlWnNCVkeHUh?=
G-402	NY\ZUndjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmD4TWM2OD1yLkC2OFYh\|ryP	MV3TRW5ITVJ?
ES1	NYnnSpRGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkDETWM2OD1yLkC3NVQ3KM7:TR?=	MYnTRW5ITVJ?
L-363	NWrqPIo1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHG2eY5KSzVyPUCuNFc{QSEQvF2=	NX7tWGRsW0GQR1XS
A4-Fuk	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV\JR\|UxRTBwMEe0PFYh\|ryP	NED5bFlUSU6JRWK=
OC-314	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVrJR\|UxRTBwMEe4NFch\|ryP	MknSV2FPT0WU
SK-LU-1	MnvoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGPDeoRKSzVyPUCuNFg1OjFizszN	M3H2c3NCVkeHUh?=
MDA-MB-157	MmTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEfLeHNKSzVyPUCuNFg3PTlizszN	NX60XGdRW0GQR1XS
HuP-T3	NE\PcXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWPweFFEUUN3ME2wMlA5PzFizszN	NGDDfW5USU6JRWK=
A3-KAW	NYfWPJFiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NInlTZFKSzVyPUCuNFg5ODZizszN	NH\pXnFUSU6JRWK=
MOLT-16	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF7KemRKSzVyPUCuNFg5ODdizszN	M4\sfnNCVkeHUh?=
COLO-679	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkW3TWM2OD1yLkC5NFkyKM7:TR?=	NUXZdVdEW0GQR1XS
EM-2	NUPDO49UT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX;JR\|UxRTBwMEm5NFMh\|ryP	MUnTRW5ITVJ?
ES8	NV;XeI9TT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnznTWM2OD1yLkC5PVE5KM7:TR?=	M2rYS3NCVkeHUh?=
SK-MEL-2	NX7j[5lIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mm\TTWM2OD1yLkGwNFM{KM7:TR?=	NH[4XolUSU6JRWK=
ES3	NYfaNIVkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1Htd2lEPTB;MD6xNFIh\|ryP	M2DsWnNCVkeHUh?=
HSC-4	MoDqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1vWVmlEPTB;MD6xNFU2PCEQvF2=	NUj5fGFtW0GQR1XS
697	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlTDTWM2OD1yLkGxNFY{KM7:TR?=	MX\TRW5ITVJ?
TGBC11TKB	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVTJR\|UxRTBwMUGwPVMh\|ryP	MmLaV2FPT0WU
SK-PN-DW	MkK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml3WTWM2OD1yLkGxPFYh\|ryP	M{HpcHNCVkeHUh?=
H9	MkPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn\GTWM2OD1yLkGyNVY2KM7:TR?=	NGrmVI5USU6JRWK=
NCI-H2122	NIrEdIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlPXTWM2OD1yLkGyNlUh\|ryP	M4HE[3NCVkeHUh?=
ML-2	NG\HZphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWnJR\|UxRTBwMUK0PFQh\|ryP	MlLsV2FPT0WU
MC-IXC	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXKyVG4xUUN3ME2wMlEzQDR\|IN88US=>	MnLBV2FPT0WU
KYSE-140	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{XRc2lEPTB;MD6xN\|A1OSEQvF2=	M1Pn[nNCVkeHUh?=
DOHH-2	MoPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXz1XpE3UUN3ME2wMlE{ODZ2IN88US=>	NVXoTlJyW0GQR1XS
MEL-JUSO	MnnKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4nCU2lEPTB;MD6xN\|EzQCEQvF2=	NFuy[VRUSU6JRWK=
P30-OHK	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkTHTWM2OD1yLkGzNVYh\|ryP	M3G0THNCVkeHUh?=
CTB-1	NFnrWI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVnJR\|UxRTBwMUOzNlUh\|ryP	M4Tx[HNCVkeHUh?=
ACHN	NVzOO4RUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYPJR\|UxRTBwMUOzOlkh\|ryP	MW\TRW5ITVJ?
ES5	MoLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVLJR\|UxRTBwMUO0O\|Yh\|ryP	NFPje3pUSU6JRWK=
SF539	MnzWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWjxemFzUUN3ME2wMlE{PjhizszN	Mn\pV2FPT0WU
D-283MED	NFjGe4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXLJR\|UxRTBwMUO2PFch\|ryP	MWjTRW5ITVJ?
OVCAR-5	NYHWUFZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnvZTWM2OD1yLkGzPFk1KM7:TR?=	M{XkPHNCVkeHUh?=
RPMI-8866	NU[0SoRDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MonkTWM2OD1yLkGzPVI2KM7:TR?=	M3XLW3NCVkeHUh?=
PANC-03-27	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnX0TWM2OD1yLkG0Nlg5KM7:TR?=	NYLTfFc5W0GQR1XS
M14	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmSwTWM2OD1yLkG0OFY{KM7:TR?=	NX3VcldYW0GQR1XS
D-566MG	Ml[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3jOeWlEPTB;MD6xOFY6KM7:TR?=	Mn7NV2FPT0WU
Ramos-2G6-4C10	NYDpW2RnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV\JR\|UxRTBwMUS4OFIh\|ryP	NVvseGdZW0GQR1XS
NOS-1	M3v2ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUPJR\|UxRTBwMUS5Olch\|ryP	NIfidmZUSU6JRWK=
YH-13	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHnETIhKSzVyPUCuNVU3PzRizszN	MUHTRW5ITVJ?
NB17	NWTNZ3JTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVPyUGFCUUN3ME2wMlE2Pzh4IN88US=>	NWj1T4R{W0GQR1XS
U-2-OS	NWrQ[IhGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4HUTGlEPTB;MD6xOVg1PyEQvF2=	MYXTRW5ITVJ?
ES7	M4fCVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGnBbFBKSzVyPUCuNVYxOTFizszN	NH7mR5RUSU6JRWK=
LoVo	M4LuVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXLyOWFLUUN3ME2wMlE3OTZ4IN88US=>	NHzMUo9USU6JRWK=
QIMR-WIL	NULXOWFST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4OzVmlEPTB;MD6xOlMyOSEQvF2=	NGfC[3FUSU6JRWK=
ESS-1	MonVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4LrT2lEPTB;MD6xOlQyOyEQvF2=	NHrGeGFUSU6JRWK=
LAMA-84	NVTSfmNMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUPROIhsUUN3ME2wMlE3PTB\|IN88US=>	M{\4NHNCVkeHUh?=
TGBC24TKB	MkjIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mm\vTWM2OD1yLkG2OVM2KM7:TR?=	NWHRcnlRW0GQR1XS
KU812	Mli2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{eyWGlEPTB;MD6xOlg{KM7:TR?=	M1KwRXNCVkeHUh?=
KARPAS-45	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4DLfGlEPTB;MD6xOlg1PyEQvF2=	M2T0PXNCVkeHUh?=
ACN	NFrXV\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1q5TmlEPTB;MD6xO\|E4OSEQvF2=	MkXhV2FPT0WU
RPMI-8226	NEnyeFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVLJR\|UxRTBwMUe0OlQh\|ryP	Mn3DV2FPT0WU
GR-ST	MnO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{LRS2lEPTB;MD6xO\|gzPyEQvF2=	MVvTRW5ITVJ?
SK-UT-1	MnfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWr1eWxDUUN3ME2wMlE5PTl7IN88US=>	MlXsV2FPT0WU
SK-N-AS	MlTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M13iO2lEPTB;MD6xPFgyPSEQvF2=	NV;YdWpCW0GQR1XS
EW-1	MoDUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MljvTWM2OD1yLkG4PVA2KM7:TR?=	MWPTRW5ITVJ?
5637	NYTK[FIxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3nl[2lEPTB;MD6xPVI4QCEQvF2=	NFPye\|lUSU6JRWK=
GI-1	M{LXOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{TvPWlEPTB;MD6xPVU3OSEQvF2=	Mm\BV2FPT0WU
NCI-H1395	NFrXSFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWPTcpBuUUN3ME2wMlE6PzZzIN88US=>	NGrXZ2pUSU6JRWK=
CHP-212	NFHSVWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVLNdYNkUUN3ME2wMlE6Pzh{IN88US=>	M1Txe3NCVkeHUh?=
A427	M3PBTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF;KO21KSzVyPUCuNVk5OzJizszN	MUnTRW5ITVJ?
BE-13	NUO2fHQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYPlbIpnUUN3ME2wMlIxOTF5IN88US=>	NXvacW5bW0GQR1XS
RS4-11	MkD0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF\4RllKSzVyPUCuNlA{OThizszN	MWrTRW5ITVJ?
TI-73	NU[2NW9uT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4DPWmlEPTB;MD6yNFg4OyEQvF2=	NGDmepVUSU6JRWK=
HAL-01	M{jz[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlvsTWM2OD1yLkKwPVch\|ryP	M2HPV3NCVkeHUh?=
KY821	M3z3bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX74[phXUUN3ME2wMlIyPDJ7IN88US=>	NX31OVduW0GQR1XS
H4	M1XsWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoXPTWM2OD1yLkKyNFYzKM7:TR?=	MXXTRW5ITVJ?
EPLC-272H	M{XocWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NECwXXBKSzVyPUCuNlIxPjhizszN	MWTTRW5ITVJ?
COR-L105	M2DwdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHzvcHJKSzVyPUCuNlIzOzVizszN	Mo\uV2FPT0WU
769-P	MnniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mkn1TWM2OD1yLkKyNlk5KM7:TR?=	NVfvOoZnW0GQR1XS
HEL	MoHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGXNPFlKSzVyPUCuNlI1PTRizszN	M4\CZ3NCVkeHUh?=
VA-ES-BJ	NX;TO3ZVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX3JR\|UxRTBwMkK1OVch\|ryP	Mn3PV2FPT0WU
IST-MEL1	NFTCXHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnvITWM2OD1yLkKyOVch\|ryP	MWrTRW5ITVJ?
KYSE-270	M1LL[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mk\hTWM2OD1yLkKyOlM{KM7:TR?=	MoDxV2FPT0WU
RH-1	M4jPNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYDJR\|UxRTBwMkK2OlYh\|ryP	MX\TRW5ITVJ?
JVM-3	NUfh[XBLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWjJR\|UxRTBwMkOwN\|Yh\|ryP	MVPTRW5ITVJ?
RPMI-7951	M2G0SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX3JR\|UxRTBwMkOwOVYh\|ryP	MYDTRW5ITVJ?
JAR	M3naeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4\ISWlEPTB;MD6yN\|I{QCEQvF2=	NFrnT4pUSU6JRWK=
MOLT-4	NEn6O21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWDJR\|UxRTBwMkO4OUDPxE1?	NF;xd2RUSU6JRWK=
ALL-PO	M37hb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWjJR\|UxRTBwMkSyOFMh\|ryP	MoDJV2FPT0WU
SNU-387	M2nkcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIjSNXFKSzVyPUCuNlQ{OzlizszN	MVXTRW5ITVJ?
IGROV-1	NIm0Z4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2XtRWlEPTB;MD6yOFQxOSEQvF2=	M2P4c3NCVkeHUh?=
MPP-89	NF\C[mdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkHaTWM2OD1yLkK0OFUyKM7:TR?=	M3fMVXNCVkeHUh?=
T98G	NUPyeHZlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUiy[GVRUUN3ME2wMlI1PTZ6IN88US=>	NFrPdXBUSU6JRWK=
NCI-H510A	M3rXVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M13ZTmlEPTB;MD6yOFYzPiEQvF2=	NGnO[GpUSU6JRWK=
KOSC-2	MnqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHXJemlKSzVyPUCuNlQ3PzFizszN	NXTRRXBIW0GQR1XS
NCI-H23	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUHJR\|UxRTBwMkS3OlEh\|ryP	NYfYZmpnW0GQR1XS
MC116	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHu1S3VKSzVyPUCuNlU3PTRizszN	M1nTZXNCVkeHUh?=
8-MG-BA	M1TjSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnLkTWM2OD1yLkK1O\|Y5KM7:TR?=	NV76[VE6W0GQR1XS
ABC-1	MmW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoXNTWM2OD1yLkK2NFY1KM7:TR?=	MmroV2FPT0WU
J-RT3-T3-5	Mo[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF;IPGxKSzVyPUCuNlY3PzhizszN	MYrTRW5ITVJ?
NCI-SNU-1	NIf1ZlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH7vPYFKSzVyPUCuNlcxPTlizszN	MofXV2FPT0WU
HCC1395	NYq5PIs6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIXYTnBKSzVyPUCuNlcxQDlizszN	Ml\yV2FPT0WU
BB65-RCC	NYHTflR7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXPM[nh6UUN3ME2wMlI4ODl5IN88US=>	NInLO3NUSU6JRWK=
NCI-H1755	M3jJTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2XBTWlEPTB;MD6yO\|MxPCEQvF2=	NYXLOpB7W0GQR1XS
OVCAR-3	MnG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHfZWoRKSzVyPUCuNlc{QDVizszN	M3fPVXNCVkeHUh?=
MKN45	M2XEPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NELLeZhKSzVyPUCuNlc6QCEQvF2=	MVTTRW5ITVJ?
TYK-nu	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NInTSoNKSzVyPUCuNlgxPiEQvF2=	Mm\tV2FPT0WU
SNU-C2B	NVy4SWtTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGTTTFdKSzVyPUCuNlgyOzRizszN	M1LsUnNCVkeHUh?=
H-EMC-SS	NEPQU\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHyweYpKSzVyPUCuNlg{PTRizszN	MoCzV2FPT0WU
CAKI-1	MorUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV3ZTJJjUUN3ME2wMlI5PjhizszN	MVfTRW5ITVJ?
EW-24	NUS3[o5sT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGLLWlBKSzVyPUCuNlg6OSEQvF2=	M3fadXNCVkeHUh?=
RXF393	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NULyOFhrUUN3ME2wMlI6ODB6IN88US=>	NGfPWmxUSU6JRWK=
CCRF-CEM	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIi0eVhKSzVyPUCuNlkyPTRizszN	NEfnfI5USU6JRWK=
HOP-92	NXP5bppkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXXJR\|UxRTBwMkmyO\|kh\|ryP	NXTEU4tlW0GQR1XS
COLO-684	M1PTWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH[xR2RKSzVyPUCuNlk1ODZizszN	NEXYfmRUSU6JRWK=
NCI-H28	NFz4fWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIPJNZpKSzVyPUCuNlk4ODRizszN	MWTTRW5ITVJ?
HuO9	NXPTSmF{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4PSTmlEPTB;MD6yPVc6OyEQvF2=	MVvTRW5ITVJ?
SF295	MlzhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn;xTWM2OD1yLkK5PFAzKM7:TR?=	NFfrV3RUSU6JRWK=
COLO-829	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEOye3lKSzVyPUCuNlk5PDVizszN	MnfaV2FPT0WU
MSTO-211H	MoftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVPvbWhXUUN3ME2wMlI6QDV3IN88US=>	M1TVXnNCVkeHUh?=
MDA-MB-361	M2fBOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NED1T4xKSzVyPUCuNlk5QTZizszN	M{n1enNCVkeHUh?=
FTC-133	NWH1cVBHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV[1RlByUUN3ME2wMlMxOjZ3IN88US=>	NXjZZ\|hqW0GQR1XS
Mewo	MnvBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MljoTWM2OD1yLkOwOFMyKM7:TR?=	MoLWV2FPT0WU
HCC70	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXTJR\|UxRTBwM{C2OlUh\|ryP	MUDTRW5ITVJ?
BB30-HNC	NIfCSXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHnnNVBKSzVyPUCuN\|E2OjVizszN	Mo\VV2FPT0WU
LCLC-97TM1	NWHBWoFIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYfVOHd1UUN3ME2wMlMyPTZ4IN88US=>	NGK5d3ZUSU6JRWK=
HCC2998	NH;PSlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXPJR\|UxRTBwM{G2OUDPxE1?	NE\hXmtUSU6JRWK=
NBsusSR	MnW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NU\nVnFwUUN3ME2wMlMyQDF7IN88US=>	M3XnWnNCVkeHUh?=
OVCAR-4	MkTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGrpWWZKSzVyPUCuN\|IxOjFizszN	M{\Ke3NCVkeHUh?=
NCI-H209	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmjITWM2OD1yLkOyN\|U{KM7:TR?=	MofIV2FPT0WU
ChaGo-K-1	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXrne3A6UUN3ME2wMlMzPDh7IN88US=>	MVrTRW5ITVJ?
KALS-1	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmfXTWM2OD1yLkOyOVk1KM7:TR?=	MoDiV2FPT0WU
D-423MG	NULIfmN5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkjiTWM2OD1yLkOzNVQzKM7:TR?=	NFLubm1USU6JRWK=
Detroit562	NGXtbWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnfUTWM2OD1yLkOzN\|Q{KM7:TR?=	NFH6UZRUSU6JRWK=
HT-144	MmryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIrZbWRKSzVyPUCuN\|M5OSEQvF2=	NHziOJhUSU6JRWK=
MEG-01	Mnv5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFfGV4xKSzVyPUCuN\|Q2QDRizszN	NVuzVmZZW0GQR1XS
BV-173	MlOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVy3dIQ2UUN3ME2wMlM1PTl4IN88US=>	MY\TRW5ITVJ?
MZ7-mel	M2S4b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH:2RlVKSzVyPUCuN\|Q3PzdizszN	M3zI[3NCVkeHUh?=
C32	M{DOWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFn1NZlKSzVyPUCuN\|Q3QDJizszN	M3qwR3NCVkeHUh?=
DU-4475	M3HXU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVT3cHhIUUN3ME2wMlM1QDd3IN88US=>	MoDFV2FPT0WU
KP-N-YN	NGjQSI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUPWNFVTUUN3ME2wMlM1QDh5IN88US=>	MWPTRW5ITVJ?
MKN1	NH;KdnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWTnNHVrUUN3ME2wMlM2ODB{IN88US=>	NGnOb\|NUSU6JRWK=
8505C	NUjLOohTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlHUTWM2OD1yLkO1NFAzKM7:TR?=	MlTXV2FPT0WU
OVCAR-8	Ml3OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYXJR\|UxRTBwM{W1PFQh\|ryP	NYnBWFljW0GQR1XS
NH-12	MkjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoC2TWM2OD1yLkO1Olk3KM7:TR?=	NGfBW3JUSU6JRWK=
COR-L88	NWDqNm9ET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1f1O2lEPTB;MD6zOlQ5OiEQvF2=	NVn0R3VpW0GQR1XS
T-24	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGHoNnBKSzVyPUCuN\|Y6QDVizszN	MVPTRW5ITVJ?
MIA-PaCa-2	M{O3PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NULWRY5xUUN3ME2wMlM4PDl5IN88US=>	MYjTRW5ITVJ?
LS-411N	M{PvTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Moj1TWM2OD1yLkO3OlA3KM7:TR?=	Mm\6V2FPT0WU
TK10	MontS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX;JR\|UxRTBwM{e5OFgh\|ryP	M13CfXNCVkeHUh?=
SW1990	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYrP[XpUUUN3ME2wMlM5OzV\|IN88US=>	MmTmV2FPT0WU
GAMG	NGD0[4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmHqTWM2OD1yLkO4OVY4KM7:TR?=	NFL0OFZUSU6JRWK=
G-361	M{HsRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M37zNmlEPTB;MD6zPFcyOiEQvF2=	MVzTRW5ITVJ?
Ca-Ski	M4jxNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3zCXGlEPTB;MD6zPFc6OiEQvF2=	NX7FN\|FkW0GQR1XS
786-0	NHjmWFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHLNW\|FKSzVyPUCuN\|g5OjNizszN	MW\TRW5ITVJ?
MHH-NB-11	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHzmfG5KSzVyPUCuN\|g6PyEQvF2=	MoTKV2FPT0WU
OE33	NXX5c45tT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1[1WmlEPTB;MD6zPVEyQCEQvF2=	NWHQZZo1W0GQR1XS
SW954	M1LCVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1mybWlEPTB;MD60NFE{OSEQvF2=	M1HqT3NCVkeHUh?=
KYSE-180	NX;D[XRyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEm2clBKSzVyPUCuOFAyPTFizszN	M{\DSHNCVkeHUh?=
NCI-H720	NXzXR2lTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{TlU2lEPTB;MD60NFE6OSEQvF2=	MoX0V2FPT0WU
COR-L23	NVHTPWtTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml6xTWM2OD1yLkSwNlg3KM7:TR?=	MUXTRW5ITVJ?
PFSK-1	M{HZ[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnvTTWM2OD1yLkSxNFkzKM7:TR?=	M3;KVHNCVkeHUh?=
FADU	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXOzfVZKUUN3ME2wMlQyOTd{IN88US=>	NHjYdYZUSU6JRWK=
GP5d	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkO4TWM2OD1yLkSxNlI2KM7:TR?=	NWSyRnc1W0GQR1XS
PC-14	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXPGOVhXUUN3ME2wMlQyPjZzIN88US=>	NVjVWI1IW0GQR1XS
SJSA-1	NILnWnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIL1SZBKSzVyPUCuOFE4OTRizszN	Mn;xV2FPT0WU
D-336MG	M13zXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1r5bWlEPTB;MD60NlE{QCEQvF2=	MV7TRW5ITVJ?
LOXIMVI	M4ryVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlnFTWM2OD1yLkSyPFg2KM7:TR?=	NFO4c45USU6JRWK=
EFO-27	M4jCfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M33RfmlEPTB;MD60N\|A1QSEQvF2=	NYfYVXlVW0GQR1XS
A2780	NXj5d3FQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHPjO4xKSzVyPUCuOFMyPjJizszN	MVLTRW5ITVJ?
CAL-12T	M1juSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmTBTWM2OD1yLkSzNlg5KM7:TR?=	NFLMfI1USU6JRWK=
ES6	NGT5S5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHS5dXlKSzVyPUCuOFQyQDVizszN	MmPHV2FPT0WU
HCE-T	M3PBRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHPyTolKSzVyPUCuOFQyQDdizszN	NYiwRoZlW0GQR1XS
SK-MES-1	NHe5XoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXHJR\|UxRTBwNESyPVMh\|ryP	MVLTRW5ITVJ?
Daoy	Mmq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnzJTWM2OD1yLkS1NVA{KM7:TR?=	MULTRW5ITVJ?
A2058	NFPiU\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M165d2lEPTB;MD60OVE{PiEQvF2=	MYDTRW5ITVJ?
Hs-578-T	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGDWWW5KSzVyPUCuOFUzPzhizszN	M33UTHNCVkeHUh?=
TE-11	NXjx[Gk{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3P4Z2lEPTB;MD60OVI6OyEQvF2=	MlzqV2FPT0WU
GI-ME-N	NYPtdnpzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFjKNYVKSzVyPUCuOFU1PiEQvF2=	MYLTRW5ITVJ?
D-392MG	NVjVfmdST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGjaTG5KSzVyPUCuOFU3OTJizszN	MVnTRW5ITVJ?
MOLT-13	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYfJR\|UxRTBwNE[yPVQh\|ryP	NX7vdoFUW0GQR1XS
SK-NEP-1	NIH2OFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGjUXmVKSzVyPUCuOFY1OTlizszN	MYHTRW5ITVJ?
KS-1	NFPk[3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUnSSY1YUUN3ME2wMlQ3PjB\|IN88US=>	M2W3O3NCVkeHUh?=
HuP-T4	NGSwRZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYjJR\|UxRTBwNE[4Olgh\|ryP	MUDTRW5ITVJ?
NCI-H1563	NGX6WolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIDKUWhKSzVyPUCuOFcxOzVizszN	M3\hO3NCVkeHUh?=
U031	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2K4W2lEPTB;MD60PFI{PCEQvF2=	MmPuV2FPT0WU
HSC-3	NFrJcHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2DzWWlEPTB;MD60PFYzPiEQvF2=	NF\TUWpUSU6JRWK=
HT-3	NIPodZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYDJR\|UxRTBwNEmwN{DPxE1?	NEL2e5pUSU6JRWK=
HGC-27	NGXYUHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoG1TWM2OD1yLkS5NVE2KM7:TR?=	NFP5XGtUSU6JRWK=
HT-1080	NW\FRZRJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYHJR\|UxRTBwNEmyO{DPxE1?	NWnYXHF2W0GQR1XS
RT-112	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYHJR\|UxRTBwNEm5NlEh\|ryP	MV3TRW5ITVJ?
A375	MkDUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3vEeGlEPTB;MD60PVkzOiEQvF2=	M2nrSHNCVkeHUh?=
SW626	MkLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2Drd2lEPTB;MD61NFY{OyEQvF2=	MmK1V2FPT0WU
SBC-5	NYnjc\|B6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4TqPGlEPTB;MD61NVM1PCEQvF2=	NXrEbJpkW0GQR1XS
CAL-51	M1zndGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYT6eW5{UUN3ME2wMlUyPDN5IN88US=>	MVzTRW5ITVJ?
RKO	NYTKSplXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYXXZll7UUN3ME2wMlUzODF7IN88US=>	MoHBV2FPT0WU
HC-1	MnGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmmzTWM2OD1yLkWyNVE1KM7:TR?=	NYrCPIdiW0GQR1XS
CHL-1	MlPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX;Q[3JsUUN3ME2wMlUzPTVzIN88US=>	MVXTRW5ITVJ?
SK-N-DZ	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVzKdJdDUUN3ME2wMlU{ODd6IN88US=>	NVfkUJRQW0GQR1XS
SNU-423	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4HUd2lEPTB;MD61N\|Q3PiEQvF2=	MmnUV2FPT0WU
NB13	M4Xuemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV;icZdTUUN3ME2wMlU{PjV5IN88US=>	NXr3S5o6W0GQR1XS
EW-16	MlXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NY\FOotNUUN3ME2wMlU{Pzd2IN88US=>	NYHaVVRWW0GQR1XS
A704	NWnrU2tHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFn1OoFKSzVyPUCuOVM5QDFizszN	NGK4bWRUSU6JRWK=
Ca9-22	NX;xWlc5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2PjWmlEPTB;MD61OFA4PyEQvF2=	MnPLV2FPT0WU
NCI-H1299	MnXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkPDTWM2OD1yLkW1OVgh\|ryP	M1nYdXNCVkeHUh?=
LB771-HNC	NGjDV2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFO5fmdKSzVyPUCuOVU6OzNizszN	M17zbnNCVkeHUh?=
EW-11	M{HWVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEfpWFhKSzVyPUCuOVY{OjZizszN	MkH1V2FPT0WU
LC-2-ad	M1Pufmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF72b29KSzVyPUCuOVY2OjJizszN	NIfW[\|dUSU6JRWK=
KNS-62	MlnMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUnJR\|UxRTBwNU[1OVMh\|ryP	MVrTRW5ITVJ?
CAL-62	NW\oW3N[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mnm5TWM2OD1yLkW3NVIyKM7:TR?=	NYjkUmw1W0GQR1XS
SF126	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXPJR\|UxRTBwNUe0NlEh\|ryP	NUTiRlU3W0GQR1XS
OMC-1	NFHERZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVLJR\|UxRTBwNUe0PVch\|ryP	M2\QOnNCVkeHUh?=
AGS	NYi1bFRiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEPzTYtKSzVyPUCuOVgyPjJizszN	MV\TRW5ITVJ?
EW-22	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIK3O4ZKSzVyPUCuOVg{PzVizszN	NHL5ZnlUSU6JRWK=
KP-N-YS	NF74eXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXnJR\|UxRTBwNUizPFIh\|ryP	NF3nNYhUSU6JRWK=
BFTC-909	NEfQZmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3HpTmlEPTB;MD61PFg{OyEQvF2=	MUfTRW5ITVJ?
PSN1	NF7keVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVnJR\|UxRTBwNUmxNVgh\|ryP	NGq1UmRUSU6JRWK=
NB10	M13kRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2\XSGlEPTB;MD61PVEzQSEQvF2=	MVHTRW5ITVJ?
COLO-800	M4TxZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUfsS25zUUN3ME2wMlYxOzJ6IN88US=>	M4nsRnNCVkeHUh?=
647-V	NV;lXXRsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MljsTWM2OD1yLk[xO\|g4KM7:TR?=	MnPHV2FPT0WU
VM-CUB-1	M4TsW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVTJ[Ig3UUN3ME2wMlYyQDZzIN88US=>	Ml7ZV2FPT0WU
OS-RC-2	M125[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1\kfmlEPTB;MD62NlAyKM7:TR?=	MnvUV2FPT0WU
IST-SL1	M2O1bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGX6NWZKSzVyPUCuOlI4QDhizszN	MVTTRW5ITVJ?
NCI-H661	NV;xTXp2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWfMRnpMUUN3ME2wMlY{PzF{IN88US=>	MYPTRW5ITVJ?
ETK-1	M{\qS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXzJR\|UxRTBwNkO3NlEh\|ryP	NFHmSVhUSU6JRWK=
SW1710	NYPre29YT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M13O[mlEPTB;MD62OFAzOyEQvF2=	MXTTRW5ITVJ?
GCT	MkHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1TOeWlEPTB;MD62OFk{PSEQvF2=	Mor4V2FPT0WU
SKG-IIIa	M4HnVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3zGeWlEPTB;MD62OVA{PiEQvF2=	NV\SRXAyW0GQR1XS
LU-134-A	NXzhPXZqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIPZNJJKSzVyPUCuOlU3PSEQvF2=	MnrLV2FPT0WU
Becker	M3jhZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFf2VItKSzVyPUCuOlU5ODVizszN	Mn[yV2FPT0WU
PANC-08-13	NEDOPWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHTZb2dKSzVyPUCuOlYxPjhizszN	MVnTRW5ITVJ?
SW620	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1GzWGlEPTB;MD62OlIzOyEQvF2=	NF62[\|ZUSU6JRWK=
AsPC-1	NFfMdpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnS5TWM2OD1yLk[2N\|YyKM7:TR?=	Mk[xV2FPT0WU
LXF-289	NF7sfoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2H4cWlEPTB;MD62O\|YzPSEQvF2=	MoTyV2FPT0WU
RERF-LC-MS	NYnTNZZmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX7yd4tQUUN3ME2wMlY4PjdzIN88US=>	MnvVV2FPT0WU
NCI-H1355	MmfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUPJR\|UxRTBwNke4OVIh\|ryP	NETsT45USU6JRWK=
23132-87	NF\6dIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkixTWM2OD1yLk[4N\|A3KM7:TR?=	M{[2eXNCVkeHUh?=
BHY	MmXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXy4OYEzUUN3ME2wMlY5QDB2IN88US=>	NW\WU2xLW0GQR1XS
C2BBe1	M17iPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWHhOpFxUUN3ME2wMlY5QTJ6IN88US=>	Ml3jV2FPT0WU
A172	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXLJR\|UxRTBwNkmyNVch\|ryP	MojOV2FPT0WU
NCI-H727	MnHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFPyPZFKSzVyPUCuOlk5OTJizszN	MVvTRW5ITVJ?
NB69	NGG2Oo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4TvVWlEPTB;MD63NFU1QSEQvF2=	NFvMTZhUSU6JRWK=
HCC1937	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnXlTWM2OD1yLkewOlMyKM7:TR?=	NFS4cFNUSU6JRWK=
HuCCT1	NWnqZVFET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3\CWGlEPTB;MD63NFc3PSEQvF2=	M3O3XnNCVkeHUh?=
HH	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFLBOmNKSzVyPUCuO\|A4QDFizszN	MUnTRW5ITVJ?
MN-60	NFW2PXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFXrbVZKSzVyPUCuO\|IyOjRizszN	MYTTRW5ITVJ?
CFPAC-1	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlXCTWM2OD1yLkeyNlU4KM7:TR?=	M3zEW3NCVkeHUh?=
HOP-62	MlzTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWPJR\|UxRTBwN{K2NkDPxE1?	NVm0UZZMW0GQR1XS
EW-3	NETh[YJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGP3flNKSzVyPUCuO\|M2PTJizszN	NGXMbGJUSU6JRWK=
SW1417	NXO4PIR2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3u1U2lEPTB;MD63N\|U6OyEQvF2=	MnO4V2FPT0WU
NCI-H1155	NG[xN2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVfJR\|UxRTBwN{O4OlQh\|ryP	MYLTRW5ITVJ?
CAL-54	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUnJR\|UxRTBwN{SwN{DPxE1?	MWDTRW5ITVJ?
Saos-2	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{XsTWlEPTB;MD63OFU5PCEQvF2=	MV;TRW5ITVJ?
NCI-H446	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoDFTWM2OD1yLke0PFA3KM7:TR?=	MWHTRW5ITVJ?
LS-513	MkXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3jtWWlEPTB;MD63OFkxQCEQvF2=	MkLyV2FPT0WU
PA-1	NWHZeYg1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF[xVmZKSzVyPUCuO\|Q6PjhizszN	M2XjSXNCVkeHUh?=
HCC38	M2T2VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoKyTWM2OD1yLke0PVg1KM7:TR?=	MkK0V2FPT0WU
DMS-273	MmHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWnJR\|UxRTBwN{W0OVYh\|ryP	M1HuOnNCVkeHUh?=
U-266	M3vxe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoTnTWM2OD1yLke2NlYzKM7:TR?=	M1;mPXNCVkeHUh?=
HL-60	Moj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEDQSYNKSzVyPUCuO\|c{PTVizszN	MoLOV2FPT0WU
UACC-62	M{P1OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVXC[HVCUUN3ME2wMlc4PTV\|IN88US=>	NGr6[FlUSU6JRWK=
DoTc2-4510	Mme5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVOyfZJsUUN3ME2wMlc5OjFzIN88US=>	NYDwV49ZW0GQR1XS
SW982	M{DPfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkPWTWM2OD1yLke4OFMzKM7:TR?=	MmC4V2FPT0WU
8305C	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXqx[WRlUUN3ME2wMlc5QTN7IN88US=>	NEHvfGFUSU6JRWK=
SW48	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4jvc2lEPTB;MD63PVI1KM7:TR?=	M3LBU3NCVkeHUh?=
NB5	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHOydYFKSzVyPUCuO\|k3PTFizszN	NIK3NmFUSU6JRWK=
J82	MkHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEPYWGpKSzVyPUCuPFA1QDdizszN	NUnzXoxRW0GQR1XS
HDLM-2	NWLFTXZvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M332dWlEPTB;MD64NVM1QSEQvF2=	MYPTRW5ITVJ?
HEC-1	NGXoOFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYm1S5R{UUN3ME2wMlgyOzdzIN88US=>	NF;WWZNUSU6JRWK=
AU565	MkmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFXleohKSzVyPUCuPFI1PCEQvF2=	MlnyV2FPT0WU
KYSE-520	NInDXGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4jtSGlEPTB;MD64NlY{PiEQvF2=	NXfW[Y4{W0GQR1XS
HTC-C3	NF3wUIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mk\TTWM2OD1yLkizOFc1KM7:TR?=	MmT6V2FPT0WU
AN3-CA	Mlm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIDRVYZKSzVyPUCuPFM4OTFizszN	M3O0fHNCVkeHUh?=
KG-1	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHrVUWRKSzVyPUCuPFQ1QDRizszN	MU\TRW5ITVJ?
NCI-N87	NUjhRY06T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3j5XmlEPTB;MD64OFU2PiEQvF2=	Mnu5V2FPT0WU
HN	NYi3cm5{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWXhVo5iUUN3ME2wMlg1PTlzIN88US=>	MUjTRW5ITVJ?
SiHa	MnLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MULJR\|UxRTBwOEW4PFIh\|ryP	NEC0ZnRUSU6JRWK=
C-33-A	M2f5[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVfJR\|UxRTBwOE[xPFUh\|ryP	NFTrWJdUSU6JRWK=
A673	NWHZXllZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWXJR\|UxRTBwOE[1N\|Yh\|ryP	NFTpOJNUSU6JRWK=
HSC-2	M3HZ[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{X2PGlEPTB;MD64O\|M{PCEQvF2=	MojiV2FPT0WU
LN-405	M1TPWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGq2VIRKSzVyPUCuPFc4OzFizszN	NWPjOpFkW0GQR1XS
HOS	NIXqcWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV3iZYxGUUN3ME2wMlg4QTl3IN88US=>	NF[2bpJUSU6JRWK=
SF268	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWDJR\|UxRTBwOEiwPVch\|ryP	M{Dwb3NCVkeHUh?=
DJM-1	M1;wT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1HLUGlEPTB;MD64PFYxOiEQvF2=	MWDTRW5ITVJ?
HT-29	NXjURnJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mmn3TWM2OD1yLki5OFE4KM7:TR?=	MX3TRW5ITVJ?
NCI-H292	M1\VVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkfITWM2OD1yLki5O\|c4KM7:TR?=	NVPtZ3Y1W0GQR1XS
UM-UC-3	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH3LSWlKSzVyPUCuPVA{OTZizszN	NYe2eINLW0GQR1XS
VMRC-RCZ	M{jX[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHTrXnVKSzVyPUCuPVA2PzhizszN	NGP2coxUSU6JRWK=
D-263MG	NUjBPXRLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mm[3TWM2OD1yLkmwPVQ{KM7:TR?=	M17Gc3NCVkeHUh?=
TE-10	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmL2TWM2OD1yLkmwPVg1KM7:TR?=	NE\YNXBUSU6JRWK=
SW1088	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn\2TWM2OD1yLkmxOVUzKM7:TR?=	NXjMcFViW0GQR1XS
NCI-H1048	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M334eGlEPTB;MD65NVg2OiEQvF2=	MmXvV2FPT0WU
A431	NEHDOIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml;kTWM2OD1yLkmyOFUzKM7:TR?=	NHnmSVBUSU6JRWK=
SW1783	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFryPJhKSzVyPUCuPVMzPTFizszN	NUD2UlZnW0GQR1XS
NCI-H2452	NVz4dIZFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkOyTWM2OD1yLkmzOVU4KM7:TR?=	NFLRfJVUSU6JRWK=
OAW-42	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{XEW2lEPTB;MD65N\|Y3PSEQvF2=	NV23fHdlW0GQR1XS
HuO-3N1	NID3SpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M176fmlEPTB;MD65OFA6OiEQvF2=	MoLIV2FPT0WU
K5	NF\nNXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1rYbWlEPTB;MD65OFEzPyEQvF2=	M3jNTHNCVkeHUh?=
SW1573	MmDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUn5fZYyUUN3ME2wMlk1OjJ5IN88US=>	MYDTRW5ITVJ?
NCI-H1792	NX3rN5N4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkPwTWM2OD1yLkm0NlM4KM7:TR?=	MVPTRW5ITVJ?
HCC1187	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWLJR\|UxRTBwOU[3OFkh\|ryP	MXjTRW5ITVJ?
HCE-4	MnPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkPaTWM2OD1yLkm2PVYh\|ryP	MYfTRW5ITVJ?
HPAF-II	MmSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV3lc2tNUUN3ME2wMlk4ODJ6IN88US=>	MVvTRW5ITVJ?
MEL-HO	NWK0[XNmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlrQTWM2OD1yLkm3PVQ2KM7:TR?=	M1zINnNCVkeHUh?=
LCLC-103H	NUOxe4tpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3TWPGlEPTB;MD65PFAzPyEQvF2=	MnPZV2FPT0WU
CAL-33	NG\0[\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVjJR\|UxRTBwOUizO\|gh\|ryP	Mn3DV2FPT0WU
NB6	MmqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV7wcXROUUN3ME2wMlk5PDZ{IN88US=>	NUjsdplXW0GQR1XS
BFTC-905	M1fKPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWTJR\|UxRTBwOUi0O\|Mh\|ryP	NELqS2dUSU6JRWK=
NMC-G1	NV;Te3plT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVHJR\|UxRTBwOUi1PVIh\|ryP	M3vQfHNCVkeHUh?=
RCM-1	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH\oNG9KSzVyPUCuPVkzPThizszN	MWfTRW5ITVJ?
COLO-320-HSR	NWP4fVRIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MonBTWM2OD1zLkCwOFEzKM7:TR?=	MnjNV2FPT0WU
NCI-H2030	M2nSXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MknUTWM2OD1zLkCxPFE{KM7:TR?=	MX7TRW5ITVJ?
SCC-4	M1\HUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFXrUIdKSzVyPUGuNFE5PTlizszN	MlnEV2FPT0WU
KYSE-410	NE[3O\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYDGZ45TUUN3ME2xMlA{PTJizszN	NVy2cJpTW0GQR1XS
NCI-H1650	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGfwbI1KSzVyPUGuNFM6PzFizszN	M4TaRXNCVkeHUh?=
S-117	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHTsfJVKSzVyPUGuNFQh\|ryP	M1niRnNCVkeHUh?=
GAK	MonaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX7JR\|UxRTFwMEWwO\|Uh\|ryP	NWfXeGs{W0GQR1XS
KYSE-450	NFH0[\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3zTbmlEPTB;MT6wOVM{PiEQvF2=	M{jiWHNCVkeHUh?=
M059J	NIT5T4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH[1ZXlKSzVyPUGuNFY5OjhizszN	NVHnUnlZW0GQR1XS
LAN-6	MmXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV33OZVyUUN3ME2xMlA4Pzd\|IN88US=>	M2nkbHNCVkeHUh?=
NCI-H1651	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{XhcWlEPTB;MT6wPVM2OiEQvF2=	Moq3V2FPT0WU
KMOE-2	NGnNcZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWHJR\|UxRTFwMUC5O\|Mh\|ryP	MnjIV2FPT0WU
SN12C	M2PXcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnzCTWM2OD1zLkGxO\|g2KM7:TR?=	NIDxSFhUSU6JRWK=
SW900	Ml\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVLJR\|UxRTFwMUKyOVEh\|ryP	MnTtV2FPT0WU
TE-8	NWnqTVhrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIrzeG9KSzVyPUGuNVIzQTFizszN	NYjQW2ZGW0GQR1XS
HO-1-N-1	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NW\OR4w5UUN3ME2xMlE1OzV\|IN88US=>	NXXJc5JWW0GQR1XS
BHT-101	NGXDU45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVrHOlNHUUN3ME2xMlE1PzF2IN88US=>	MlHMV2FPT0WU
639-V	Mk\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3rGbmlEPTB;MT6xOlY4KM7:TR?=	Mm\RV2FPT0WU
RVH-421	NUHGVIFlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkPHTWM2OD1zLkG5N\|Q4KM7:TR?=	NUTVeVZuW0GQR1XS
SW780	Ml7lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MknaTWM2OD1zLkG5OVE2KM7:TR?=	NEPzOZdUSU6JRWK=
SNB75	NIHLZodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1nCSmlEPTB;MT6xPVgyQSEQvF2=	NHfrSYVUSU6JRWK=
U-87-MG	Ml7QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoHvTWM2OD1zLkKxN\|M1KM7:TR?=	M{LH[nNCVkeHUh?=
TE-1	NYDN[nV1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXXGVIZ4UUN3ME2xMlIyOzZ5IN88US=>	NH3CbHFUSU6JRWK=
CAS-1	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH[5c2dKSzVyPUGuNlE1OThizszN	NUnX[lVzW0GQR1XS
MKN7	NWX3VIhGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mk\HTWM2OD1zLkKxOFc5KM7:TR?=	M2T4UnNCVkeHUh?=
KM-H2	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGPOVpNKSzVyPUGuNlE4PzNizszN	M2DTT3NCVkeHUh?=
NCI-H1693	M2W2PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoLoTWM2OD1zLkKyO\|U5KM7:TR?=	NXLwNYxrW0GQR1XS
KGN	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnHJTWM2OD1zLkKzN\|U6KM7:TR?=	MVrTRW5ITVJ?
NCI-H2347	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1vpO2lEPTB;MT6yN\|UzPSEQvF2=	NWXzS3pYW0GQR1XS
MFM-223	M1\wSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV3mZlc{UUN3ME2xMlI1OzR\|IN88US=>	NVP4UIRWW0GQR1XS
OCI-AML2	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWLJR\|UxRTFwMk[2OlYh\|ryP	MXPTRW5ITVJ?
SAS	M1rTeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmLiTWM2OD1zLkK2OlczKM7:TR?=	Mm\XV2FPT0WU
BT-549	NXHwdlVPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlXmTWM2OD1zLkK2O\|gzKM7:TR?=	MUfTRW5ITVJ?
NCI-H2228	NEfrd4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlyzTWM2OD1zLkK4OlQh\|ryP	NXTHRmpNW0GQR1XS
BxPC-3	Ml3yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX\JR\|UxRTFwM{C2O\|Ih\|ryP	NFvNdmpUSU6JRWK=
SCH	M{S0OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXP6RmhSUUN3ME2xMlMzPTB\|IN88US=>	NEfRRWFUSU6JRWK=
GMS-10	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoPUTWM2OD1zLkO0OVUyKM7:TR?=	NFTNPYxUSU6JRWK=
GB-1	M1XiT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXvJR\|UxRTFwM{e1OlQh\|ryP	MXHTRW5ITVJ?
NCI-H520	NIi1NoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVrJR\|UxRTFwM{ixOlgh\|ryP	NUPNToRwW0GQR1XS
GCIY	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXnJR\|UxRTFwM{mwOVEh\|ryP	MYDTRW5ITVJ?
HuH-7	NXviXI5xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2TyWGlEPTB;MT6zPVUxOSEQvF2=	NYPXWnhEW0GQR1XS
IA-LM	M37LfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3fHZ2lEPTB;MT6zPVk5PiEQvF2=	MV;TRW5ITVJ?
BB49-HNC	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWnJR\|UxRTFwNECyN\|Eh\|ryP	MWPTRW5ITVJ?
Calu-6	MmfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYr4elN6UUN3ME2xMlQyOTh5IN88US=>	NILwOZdUSU6JRWK=
NCI-H650	NF\HNY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVrJR\|UxRTFwNEG3PVUh\|ryP	M{fLdHNCVkeHUh?=
TE-5	M2rwW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXHEeXVTUUN3ME2xMlQyQTV2IN88US=>	NHXoXJFUSU6JRWK=
KINGS-1	NGjxPYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWDJR\|UxRTFwNEKwNVgh\|ryP	MY\TRW5ITVJ?
HCT-116	MlHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFTPNXVKSzVyPUGuOFIyPzZizszN	MoXVV2FPT0WU
NCI-H1573	NIq4TWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX7GXIk5UUN3ME2xMlQzOjV5IN88US=>	NHLUOGlUSU6JRWK=
NCI-H358	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1vnVmlEPTB;MT60N\|EzQCEQvF2=	NVXqcmdWW0GQR1XS
LNCaP-Clone-FGC	M3;TPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWq0R\|dFUUN3ME2xMlQ1OzF7IN88US=>	MnjjV2FPT0WU
KP-4	M{LSWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1HKS2lEPTB;MT60OlE2OSEQvF2=	MVTTRW5ITVJ?
LK-2	M13yd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV\JR\|UxRTFwNE[zPFIh\|ryP	NXHEcFBsW0GQR1XS
EFM-19	M4[yW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFzXSVVKSzVyPUGuOFgyODRizszN	MknKV2FPT0WU
GT3TKB	NUPPOXU2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnHhTWM2OD1zLkS4OlE{KM7:TR?=	MVnTRW5ITVJ?
A549	NF7yZpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWPJR\|UxRTFwNEi4N\|Mh\|ryP	NYHaeJBVW0GQR1XS
no-11	NELTfIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVLyZ5NCUUN3ME2xMlQ6ODJ4IN88US=>	M1[2OHNCVkeHUh?=
SK-N-FI	M1zCSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnzmTWM2OD1zLkS5N\|gh\|ryP	MnO3V2FPT0WU
NCI-H2170	NIH3fXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIf6bG5KSzVyPUGuOVI{OTNizszN	NYXsVYoxW0GQR1XS
NCI-H460	NGjlZolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUn2cI4yUUN3ME2xMlUzQTZzIN88US=>	MVPTRW5ITVJ?
NCI-H526	Mm\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn6yTWM2OD1zLkWzO\|A3KM7:TR?=	NUHTWVVYW0GQR1XS
KYSE-510	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MljaTWM2OD1zLkW4NlUh\|ryP	MWrTRW5ITVJ?
YKG-1	NF3Q[25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX:wOHNHUUN3ME2xMlU5OzJ6IN88US=>	MV3TRW5ITVJ?
EW-18	NFzScINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoWzTWM2OD1zLk[wNlI4KM7:TR?=	NHjWNFNUSU6JRWK=
MDA-MB-231	M1jhZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVK0cIJOUUN3ME2xMlYxOzhizszN	NELzdZdUSU6JRWK=
HT55	NHvjN4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmfMTWM2OD1zLk[wOVkyKM7:TR?=	NXzBd29IW0GQR1XS
NCI-H1793	M4TF[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWLHbIFyUUN3ME2xMlYyOzR3IN88US=>	NEThXHpUSU6JRWK=
TE-9	NYHmdVkxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3;tNGlEPTB;MT62N\|Q2PiEQvF2=	NI\PNmdUSU6JRWK=
DSH1	M{GyOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFHySZlKSzVyPUGuOlkzPTZizszN	NE\pZmxUSU6JRWK=
A101D	M3nNNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYfJR\|UxRTFwNkm5PFMh\|ryP	NIjQOG5USU6JRWK=
DB	M3LTfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH:0OVZKSzVyPUGuO\|AxPjdizszN	NHnPe\|RUSU6JRWK=
ME-180	M17jUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYLJR\|UxRTFwN{G3PFUh\|ryP	MV7TRW5ITVJ?
BT-20	MkLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF;DXWxKSzVyPUGuO\|I1ODdizszN	NFHzU3hUSU6JRWK=
A498	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoXHTWM2OD1zLkeyPVY{KM7:TR?=	MkfKV2FPT0WU
UMC-11	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2LPbGlEPTB;MT63Olc1QSEQvF2=	NHTQfpFUSU6JRWK=
EC-GI-10	NYj2c4h7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUDJR\|UxRTFwN{e1OVYh\|ryP	MUTTRW5ITVJ?
NCI-H630	NYnOR4JoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHe2eY9KSzVyPUGuO\|g3PDJizszN	MWXTRW5ITVJ?
EGI-1	Ml3zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{DUTWlEPTB;MT64NFI3PyEQvF2=	M1vr[3NCVkeHUh?=
22RV1	NVft[GI{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWHMWW9RUUN3ME2xMlgxQDV\|IN88US=>	NGK5UoxUSU6JRWK=
LS-123	MlfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MU\JR\|UxRTFwOEGyNVQh\|ryP	Mn20V2FPT0WU
OAW-28	M3LCbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGLOfpJKSzVyPUGuPFQ4PDZizszN	NWLvR20yW0GQR1XS
CaR-1	NVnNblk2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWrJR\|UxRTFwOEewO{DPxE1?	MWrTRW5ITVJ?
HT	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFnMN2ZKSzVyPUGuPFc{PDJizszN	M1Pv[XNCVkeHUh?=
BCPAP	M3ezdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVzJR\|UxRTFwOEi2O\|Yh\|ryP	MWDTRW5ITVJ?
RMG-I	MlvsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX63PGN2UUN3ME2xMlkxPzh5IN88US=>	M3TwPXNCVkeHUh?=
C8166	M4rScGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NY\RVmU1UUN3ME2xMlkxQTN{IN88US=>	NIfWS\|ZUSU6JRWK=
TGBC1TKB	NX30OXRmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXnTfHdyUUN3ME2xMlkzODN3IN88US=>	NITreZVUSU6JRWK=
SCC-9	M2q1[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmXFTWM2OD1zLkm5NVA2KM7:TR?=	Mn3KV2FPT0WU
EKVX	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnqxTWM2OD1{LkCwNVU1KM7:TR?=	NIHPcZVUSU6JRWK=
KU-19-19	M4OwTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmXnTWM2OD1{LkCwN\|czKM7:TR?=	MX7TRW5ITVJ?
K-562	M1XMb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4n4TGlEPTB;Mj6wNFg6QCEQvF2=	MVHTRW5ITVJ?
SW962	NEj6NppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mm\mTWM2OD1{LkC0NFU6KM7:TR?=	NUPiUnBnW0GQR1XS
MDA-MB-453	NGfzZYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWrJR\|UxRTJwMEW0OFIh\|ryP	NYG2d3B[W0GQR1XS
BPH-1	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWDJR\|UxRTJwMEewPVgh\|ryP	M4\QVnNCVkeHUh?=
DK-MG	NIrwbZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEPQUWFKSzVyPUKuNFg3ODNizszN	Mn7TV2FPT0WU
Capan-2	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4LWNGlEPTB;Mj6xNFA1OSEQvF2=	NVnVR2tHW0GQR1XS
SCC-15	NXjrZZhNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWPJR\|UxRTJwMUK1OFEh\|ryP	MnXEV2FPT0WU
DOK	NHPuXWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVXJR\|UxRTJwMUOxOFch\|ryP	MoC1V2FPT0WU
YAPC	NFnBcmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFfPcJVKSzVyPUKuNVU{ODdizszN	MXvTRW5ITVJ?
AM-38	NF\Fb4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYPJR\|UxRTJwMUewNVUh\|ryP	NYnD[Gp4W0GQR1XS
EFO-21	NWjWN5VLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVzJR\|UxRTJwMUe3PFgh\|ryP	MWPTRW5ITVJ?
A388	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEiybpNKSzVyPUKuNVkzPzFizszN	NXLR[41UW0GQR1XS
RH-18	MmTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3jKW2lEPTB;Mj6xPVM3QSEQvF2=	M4fQSHNCVkeHUh?=
NCI-H1581	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEPLUZNKSzVyPUKuNVk2QTZizszN	NV\QfoVoW0GQR1XS
COLO-668	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1XjW2lEPTB;Mj6yPVk4OyEQvF2=	MlXaV2FPT0WU
RPMI-2650	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYnJR\|UxRTJwM{K2OVkh\|ryP	Mmq1V2FPT0WU
HMV-II	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWjJR\|UxRTJwM{O4Olgh\|ryP	MnXQV2FPT0WU
NCI-H2342	NUjRZo1lT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoDVTWM2OD1{LkO0OlA{KM7:TR?=	NGrSVHhUSU6JRWK=
SH-4	NX;ZTWRnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn\vTWM2OD1{LkO4NlA1KM7:TR?=	NYnqRlJ[W0GQR1XS
L-428	NGXXfFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn:yTWM2OD1{LkO4O\|k1KM7:TR?=	NHK2[WNUSU6JRWK=
U-118-MG	M{DPcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWnvS4RuUUN3ME2yMlM6QDB3IN88US=>	NE\iWpFUSU6JRWK=
RO82-W-1	NHzWcpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHjGPWJKSzVyPUKuOFM4OjdizszN	M4P1WnNCVkeHUh?=
NCI-H2291	NIjEZpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGPXSoNKSzVyPUKuOFY6QTRizszN	NGLpOXNUSU6JRWK=
SK-OV-3	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{LsOGlEPTB;Mj61NFI1QSEQvF2=	NXTYNow6W0GQR1XS
NCI-H441	M2XzeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3XD[2lEPTB;Mj61NFMxPSEQvF2=	NV23VoM{W0GQR1XS
NCI-H2009	NEK2e2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2HMVGlEPTB;Mj61Nlk{PCEQvF2=	MYrTRW5ITVJ?
LB2518-MEL	NUjGcIZpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmTZTWM2OD1{LkWzO\|Q4KM7:TR?=	M{n2Z3NCVkeHUh?=
PANC-10-05	NU\sdnNTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWDJR\|UxRTJwNkGxNVYh\|ryP	M1v0cHNCVkeHUh?=
CAL-85-1	NYTMWWpbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVu3V\|l2UUN3ME2yMlY3OTZzIN88US=>	MWLTRW5ITVJ?
PC-3	MmjRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoDnTWM2OD1{Lk[2OlEyKM7:TR?=	NYPLNFVFW0GQR1XS
COLO-824	Mn36S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFvqfoJKSzVyPUKuOlc{PzRizszN	MnfIV2FPT0WU
D-502MG	M{nURmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHXXOmZKSzVyPUKuO\|A1ODZizszN	MkTkV2FPT0WU
SBC-1	MoOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFTUTHBKSzVyPUKuO\|E3OjdizszN	Mo\kV2FPT0WU
CAPAN-1	NVTFSIlRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmjFTWM2OD1{LkexPVQ6KM7:TR?=	NUnrV\|RXW0GQR1XS
D-247MG	NWHPVFRJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXOzSHFWUUN3ME2yMlc{PzV4IN88US=>	NF\ITnZUSU6JRWK=
CAL-39	M2LLSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkfHTWM2OD1{Lki2N\|g6KM7:TR?=	M4TkZnNCVkeHUh?=
NCI-H2087	NH3KWG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVnXcm17UUN3ME2yMlg5PDNzIN88US=>	NVLuUVlHW0GQR1XS
NB7	M2\LXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWO1bogzUUN3ME2yMlkzOTN7IN88US=>	NViwTmRVW0GQR1XS
NCI-H1437	M4PUe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWj2bZVQUUN3ME2yMlkzOjV5IN88US=>	M{TuUHNCVkeHUh?=
RD	M4DaXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVXQNZd4UUN3ME2yMlk6QTN7IN88US=>	NGe5fpBUSU6JRWK=
TCCSUP	MlLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4jtPWlEPTB;Mz6wNlY{PiEQvF2=	NEjjOHVUSU6JRWK=
MKN28	MoTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1rt[2lEPTB;Mz6wN\|Q3OyEQvF2=	Mn3pV2FPT0WU
NCI-H596	NFLHUYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MW\JR\|UxRTNwME[3NUDPxE1?	NXf2VpA1W0GQR1XS
SW948	MnnhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXjJR\|UxRTNwMEm2PVMh\|ryP	MlvKV2FPT0WU
WM-115	M{T2cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{G1UGlEPTB;Mz6xNVgzPyEQvF2=	NFPKUHVUSU6JRWK=
HCC1954	M{\Dcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MU\JR\|UxRTNwMUKxOFEh\|ryP	NHfYcIpUSU6JRWK=
MS-1	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlLpTWM2OD1\|LkG4OFc1KM7:TR?=	NYXtUXBKW0GQR1XS
SW13	NGnUb4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXfCPW0yUUN3ME2zMlI{OjZizszN	MVHTRW5ITVJ?
OE19	M4r5Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFziSFFKSzVyPUOuNlg1QDlizszN	MnTFV2FPT0WU
HT-1197	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NE\BbZJKSzVyPUOuNlkyPzlizszN	M4DGW3NCVkeHUh?=
HLE	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmjITWM2OD1\|LkOyPFEh\|ryP	M{XMOXNCVkeHUh?=
NUGC-3	M4OyRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mm\DTWM2OD1\|LkS0O\|YyKM7:TR?=	MW\TRW5ITVJ?
UACC-257	MkfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnzSTWM2OD1\|LkWyOFE4KM7:TR?=	NVi5UG9JW0GQR1XS
SK-MEL-3	NXfYXWZkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHHHRoNKSzVyPUOuOVMzOTRizszN	M1vhR3NCVkeHUh?=
KNS-81-FD	NUT0OZhGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml;QTWM2OD1\|LkW2NkDPxE1?	NVXLZZczW0GQR1XS
MZ1-PC	NYLmZ4NST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGDFNHdKSzVyPUOuOVc6QDZizszN	M1j2bnNCVkeHUh?=
KLE	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYjJR\|UxRTNwNUm4Olch\|ryP	NH6yWYpUSU6JRWK=
NCI-H2052	MmfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlnLTWM2OD1\|Lk[wNFA6KM7:TR?=	NEfoOHlUSU6JRWK=
NCI-H1838	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFX3eJNKSzVyPUOuPFEyOTlizszN	M3TjV3NCVkeHUh?=
NCI-H1623	NG\KfpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1XzXGlEPTB;ND6wNVM6PiEQvF2=	NIPST2ZUSU6JRWK=
SCC-25	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoPHTWM2OD12LkKzOVk4KM7:TR?=	M3HabnNCVkeHUh?=
CP66-MEL	NH20d2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWjJR\|UxRTRwMkWxPVEh\|ryP	M1XtOnNCVkeHUh?=
TE-12	NFWwemlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXHJR\|UxRTRwMkmyO\|Eh\|ryP	M3j3UXNCVkeHUh?=
LU-99A	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHPBNmVKSzVyPUSuN\|E{PDVizszN	MXrTRW5ITVJ?
CAMA-1	M1LDc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGnqW\|VKSzVyPUSuN\|UzKM7:TR?=	NG\xO\|NUSU6JRWK=
SK-MEL-30	NIPCNXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXi0UlJOUUN3ME20MlQyQTF\|IN88US=>	NUD4NJJGW0GQR1XS
KURAMOCHI	NVThZWtTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2XKXmlEPTB;ND60OVUzQCEQvF2=	M1LSRnNCVkeHUh?=
BEN	NV[wcmJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUnJR\|UxRTRwNUKzOlIh\|ryP	NYDjRWFJW0GQR1XS
NCI-H226	MmHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoH1TWM2OD12LkW0PFcyKM7:TR?=	MVHTRW5ITVJ?
CAL-27	M2LncGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3eySmlEPTB;ND63NVY6PCEQvF2=	MUXTRW5ITVJ?
G-401	NEPTSXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWXJR\|UxRTRwOEO4OFEh\|ryP	M4\5bnNCVkeHUh?=
CAL-120	M4fJVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVrJR\|UxRTRwOES5PVEh\|ryP	MlnwV2FPT0WU
DMS-114	Mme3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2rxWWlEPTB;NT6xOFUxPiEQvF2=	NHHDOnZUSU6JRWK=
KYSE-70	NEnvT5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3G0SWlEPTB;NT6xOFg2QSEQvF2=	NFzx[GFUSU6JRWK=
NCI-H1648	NFHPbXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnqxTWM2OD13LkK5O\|gzKM7:TR?=	NFjvb\|dUSU6JRWK=
MDA-MB-175-VII	NYPZUVB3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2OwSWlEPTB;NT60OFAyPCEQvF2=	MUTTRW5ITVJ?
NCI-H2029	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWWyXnQzUUN3ME21MlQ5ODJ{IN88US=>	MkC1V2FPT0WU
LS-1034	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVHJR\|UxRTVwNk[4PFkh\|ryP	M4L3PXNCVkeHUh?=
LB831-BLC	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlPWTWM2OD13LkewN\|Q2KM7:TR?=	NX\3fJJsW0GQR1XS
MDA-MB-415	M4Xte2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVS0XmFiUUN3ME21MlcxQDFizszN	NX7UZZhvW0GQR1XS
TE-6	NHLuXm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGDjZW5KSzVyPUWuO\|QyQDJizszN	NXHuVoUyW0GQR1XS
SK-MEL-24	MmT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYLkT4ZtUUN3ME21Mlc1PTZ2IN88US=>	MXjTRW5ITVJ?
HUTU-80	MoDDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NE\teIlKSzVyPUWuO\|U{OzNizszN	NFLPU3ZUSU6JRWK=
OCUB-M	Mk[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1r3VGlEPTB;NT63O\|U3OyEQvF2=	MYPTRW5ITVJ?
IGR-1	Mn;RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUTvXYpuUUN3ME21Mlg3QDl2IN88US=>	NFzCR4tUSU6JRWK=
NCI-H747	NYfablVMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3HhdWlEPTB;Nj6yOFU5PSEQvF2=	MV3TRW5ITVJ?
COLO-680N	NFf6fFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF7JUVJKSzVyPU[uN\|k1ODNizszN	NIf0TWNUSU6JRWK=
NB12	NGLBU4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{f4R2lEPTB;Nj63PVczOiEQvF2=	M3fPfHNCVkeHUh?=
SNU-449	NFrwU3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH70VZRKSzVyPU[uPVk2QTFizszN	MY\TRW5ITVJ?
D-542MG	M2LLPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml\HTWM2OD15LkGyNlk6KM7:TR?=	MmHNV2FPT0WU
COLO-792	NVrwe3V7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MW\JR\|UxRTdwOEexNlch\|ryP	MnfXV2FPT0WU
NCI-H810	NV7oRlVwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX;XVmk2UUN3ME24MlAzQTh2IN88US=>	MlLLV2FPT0WU
T47D	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2XVO2lEPTB;OD6xOlAzPCEQvF2=	Mk[zV2FPT0WU
Calu-3	MmDZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYPJR\|UxRThwMki4PFYh\|ryP	MkK5V2FPT0WU
COLO-741	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV;JR\|UxRThwOUOwPVMh\|ryP	M3e0NXNCVkeHUh?=
LU-135	Mo[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHnudJRKSzVyPUmuNFM1PTJizszN	NFzXdmtUSU6JRWK=
COLO-678	MnPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmnFTWM2OD17LkK4PFQ1KM7:TR?=	Mk\mV2FPT0WU
NCI-H2126	NYfJWHNLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2G4ZmlEPTB;OT6zN\|kyQSEQvF2=	M{nDfHNCVkeHUh?=
SK-MEL-28	Ml7KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2qyOmlEPTB;OT61N\|U6PiEQvF2=	MVTTRW5ITVJ?
MFE-280	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmLVTWM2OD1zMD6wNlI6KM7:TR?=	MVfTRW5ITVJ?
DBTRG-05MG	NH;ufHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWrEUHlpUUN3ME2xNE41OzZ7IN88US=>	NEn4fnFUSU6JRWK=
RCC10RGB	M4jQVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUfjVlAxUUN3ME2xNE42OjV3IN88US=>	NFWwVWhUSU6JRWK=
NTERA-S-cl-D1	NH\lZVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3zmSGlEPTB;MUCuOlg2OiEQvF2=	NGPyb4JUSU6JRWK=
C3A	MlPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXXJR\|UxRTF{LkOxO\|Ih\|ryP	MYHTRW5ITVJ?
MHH-ES-1	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX3JR\|UxRTF{LkWyPFQh\|ryP	MmnxV2FPT0WU
LU-139	NVrzc5dtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUjJR\|UxRTF{Lk[zN\|Mh\|ryP	MVHTRW5ITVJ?
KNS-42	NEnw[pVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX;JR\|UxRTF{Lki3O\|Eh\|ryP	MWXTRW5ITVJ?
MCF7	NYPTO3k6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml;GTWM2OD1zMz6yN\|Y2KM7:TR?=	NIHEVHFUSU6JRWK=
SW872	NGLTRmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmPJTWM2OD1zND61OFYyKM7:TR?=	MVfTRW5ITVJ?
HT-1376	M3r1e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M361NGlEPTB;MUSuPFU5OiEQvF2=	M36xVXNCVkeHUh?=
NCI-SNU-5	NIHpUVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2Lrc2lEPTB;MUWuNVc1OSEQvF2=	NUPVd3dUW0GQR1XS
NCI-H2405	NUL3eFh5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFOwXXJKSzVyPUG1MlQ1PzRizszN	MkTvV2FPT0WU
KYSE-150	NWfBS3NiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlH2TWM2OD1zNT63OlEyKM7:TR?=	MWXTRW5ITVJ?
SW837	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoniTWM2OD1zNj6wNVI1KM7:TR?=	MnOyV2FPT0WU
LU-65	M1TUNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1zFOmlEPTB;MUmuO\|I3KM7:TR?=	MWLTRW5ITVJ?
JEG-3	NYfwSFBUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnzzTWM2OD1{MD6zOVc4KM7:TR?=	NXfrTVFwW0GQR1XS
SK-MEL-1	M3vJSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2TH[GlEPTB;MkCuO\|g{PiEQvF2=	NID3WFBUSU6JRWK=
SK-HEP-1	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{nNNGlEPTB;MkGuOVU1OSEQvF2=	MUjTRW5ITVJ?
NCI-H1770	NYT5PW9kT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUPJR\|UxRTJ\|LkSwPFYh\|ryP	Mn\QV2FPT0WU
MG-63	M2rPSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoPaTWM2OD1{Mz63Olc{KM7:TR?=	NIr2d\|dUSU6JRWK=
ECC10	M3zyVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2nHd2lEPTB;MkWuOVcyKM7:TR?=	MUXTRW5ITVJ?
SW1463	NF\lUWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWPKSY5OUUN3ME2yO{45OzF4IN88US=>	NFTLc49USU6JRWK=
JVM-2	MlrYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHvMZXRKSzVyPUK4MlMzPDhizszN	NFnVfHpUSU6JRWK=
HCT-15	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3zVSmlEPTB;MkiuOFE6OiEQvF2=	MUHTRW5ITVJ?
CAL-72	NH3oXnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHe3cpdKSzVyPUOxMlQ6OTJizszN	MX;TRW5ITVJ?
HCC2218	M4PDUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXzJR\|UxRTN{Lki4OVgh\|ryP	NITLeVZUSU6JRWK=
BT-474	NGfENHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn7yTWM2OD1\|Mz6wPFQ{KM7:TR?=	M1LOXHNCVkeHUh?=
NCI-H1092	NF\qRZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkXqTWM2OD1\|Mz61NVQ2KM7:TR?=	NVjzbHNFW0GQR1XS
Mo-T	NGL4RXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M375SmlEPTB;M{euN\|U5PSEQvF2=	Mn3EV2FPT0WU
DU-145	NHrHOpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXnJR\|UxRTRyLk[yPVUh\|ryP	MXHTRW5ITVJ?
NCI-H1666	NH\RfpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M13ONmlEPTB;NEKuOFQ5QCEQvF2=	MX3TRW5ITVJ?
IST-MES1	NGThfZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGDtUXdKSzVyPUS2MlQyQTZizszN	MU\TRW5ITVJ?
SW1116	NHXWXFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYW3cpI3UUN3ME20PE4yPzV4IN88US=>	NUHld45JW0GQR1XS
MZ2-MEL	MlrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlntTWM2OD12OD61NFI3KM7:TR?=	MlrXV2FPT0WU

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pChk1 / Chk1 / Wee1 / p21 / p53 ; PubMed: 29963769 Cancer Med Immunoblotting analysis of CAL39 and SW954 cells showing increase in CHK1 phosphorylation after exposure to AZD7762 for 24 hours. β‐actin is used as loading control. Representative data from n = 3 experiments.	29963769
Growth inhibition assay	Cell viability; PubMed: 23715154 Cancer Discov Lkb1-wt (634, 855, and 857) and Lkb1-null (t2, t4, and t5) cell lines were plated into 96-well plates at 2000 cells/well in 150 ml medium containing the indicated concentrations of AZD7762 or CHIR124 for 3 days. Viable cells were then counted with Dojindo’s Cell Counting Kit-8 assay. The data represent mean ± SD for 3 repeats. GI50 was calculated with GraphPad.	23715154

In vivo

AZD7762 alone at 25 mg/kg shows little antitumor activity in the H460-DNp53 xenograft mice and SW620 xenograft mice, but when administrated in combination with gemcitabine (60 mg/kg), AZD7762 shows significant antitumor efficacy in the two xenografts mice with a log cell kill of 0.9 or percent treated/control (%T/C) of 26 even at low dose of 12.5 mg. Dosing of AZD7762 in combination with gemcitabine (10 mg/kg) in the H460-DNp53 xenograft rat inhibits the tumor volume in a dose-dependent manner with the %T/C values of 48 and 32 for 10 and 20 mg/kg AZD7762, respectively. AZD7762 (25 mg/kg) in combination with irinotecan (25 or 50 mg/kg) causes complete tumor regression in the SW620 xenograft mice with the %T/C increasing significantly to -66% and -67%, respectively. ^[1]

Protocol

Kinase Assay:^[1]	- Collapse Chk1 Kinase Assay: Recombinant human Chk1 is expressed as a glutathione S-transferase fusion in insect cells using a baculovirus vector and purified by glutathione affinity chromatography. A synthetic peptide substrate (N-biotinylaminohexanoyl-KKVSRSGLYRSPMPENLNRPR) for Chk1 is synthesized. Final assay concentrations of peptide and ATP (cold + 40 nCi [³³P]ATP) are 0.8 and 1 μM, respectively. Different concentrations of AZD7762, buffer containing peptide and chk1 kinase and ATP, are added sequentially to a 384-well assay plate. The plate is incubated for 2 hours, reaction is stopped by the addition of buffer containing EDTA and scintillation proximity assay beads, and plates are read using a TopCount reader. Data analysis is carried out to determinate a dose response (IC50).
Cell Research:^[1]	- Collapse Cell lines: HT29, SW620 and MDA-MB-231 cells Concentrations: Dissolved in DMSO, final concentration ~12.5 μM Incubation Time: 20 or 48 hours Method: For the checkpoint abrogation assay, HT29 cells are treated for 2 hours with camptothecin (topoisomerase I inhibitor; 0.07 μg/mL) to induce the G2 checkpoint. Cells are then treated for 20 hours with a 12-point titration of AZD7762 (12.5 μM to 6 nM) plus nocodazole. Cells are fixed with 3.7% formaldehyde for 1 hour, permeabilized with PBS containing 0.05% Triton X, and incubated with anti-phH3 antibody for 1 hour followed by Alexa Fluor 488 anti-rabbit and Hoechst stain for 1 hour. Mitotic index is determined on the ArrayScan and expressed as the percentage of cells undergoing mitosis. For the potentiation assays, SW620 or MDA-MB-231 cells are dosed for 24 hours with a 9-point titration of gemcitabine ranging from 0.01 to 100 nM with a constant dose of AZD7762 (300 nM). After 24 hours, medium is removed and AZD7762 alone is added back to the wells for an additional 24 hours. Cells are then incubated in AZD7762-free medium for an additional 72 hours. The effect on cell proliferation is determined by MTT. (Only for Reference)
Animal Research:^[1]	- Collapse Animal Models: Male NCr mice implanted s.c. with H460-DNp53 cells or SW620, and male rnu rats implanted s.c. with H460-DNp53 cells Dosages: ~25 mg/kg Administration: Injection i.v. (Only for Reference)

References

[1] Zabludoff SD, et al. Mol Cancer Ther, 2008, 7(9), 2955-2966.

Solubility (25°C)

In vitro	DMSO	50 mg/mL (137.96 mM)
	Water	Insoluble
	Ethanol	Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download AZD7762 SDF

Molecular Weight	362.42
Formula	C₁₇H₁₉FN₄O₂S
CAS No.	860352-01-8
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	C1CC(CNC1)NC(=O)C2=C(C=C(S2)C3=CC(=CC=C3)F)NC(=O)N

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
If I want to use the inhibitor for i.p. injection, can I use DMSO to dissolve it?
Answer:
Since DMSO has low toxicity with i.p. injection, hydroxyproplyl-β-cyclodextrin is consider a safer co-solvent in compound formulation. In a previous literature report, 11.3% hydroxyproplyl-β-cyclodextrin was used to formulate this compound for i.v. injection.

Chk Signaling Pathway Map

Chk Inhibitors with Unique Features

Selective CHK Inhibitor

MK-8776 (SCH 900776) : Chk1-selective, IC50=3 nM.
Most Potent CHK Inhibitor

CHIR-124 : Chk1, IC50=0.3 nM.
CHK Inhibitor in Clinical Trial

MK-8776 (SCH 900776) : Phase II for Relapsed Acute Myeloid Leukemia.
Classic CHK Inhibitor

PF-477736 : Selective, potent and ATP-competitive Chk1 inhibitor with K_i of 0.49 nM and also inhibits VEGFR2, Aurora-A, FGFR3, Flt3, Fms (CSF1R), Ret and Yes.

Related Chk Products

Ro-3306 ^New

RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with K_i of 20 nM, >15-fold selectivity against a diverse panel of human kinases. RO-3306 enhances p53-mediated Bax activation and mitochondrial apoptosis.
CCG-1423 ^New

CCG-1423 is a specific RhoA pathway inhibitor, which inhibits SRF-mediated transcription.
ML141 ^New

ML141 (CID-2950007) is demonstrated to be a potent, selective and reversible non-competitive inhibitor of Cdc42 GTPase suitable for in vitro assays, with IC50 of 200 nM and selectivity against other members of the Rho family of GTPases (Rac1, Rab2, Rab7). ML141 is associated with an increase in p38 activation and may induce p38-dependent apoptosis/senescence. ML141 also protects neuroblastoma cells from metformin-induced apoptosis.
Rabusertib (LY2603618)

Rabusertib (LY2603618, IC-83) is a highly selective Chk1 inhibitor with potential anti-tumor activity in a cell-free assay. IC50=7 nM, showing approximately 100-fold more potent against Chk1 than against any of the other protein kinases evaluated. Rabusertib (LY2603618) induces cell cycle arrest, DNA damage response and autophagy in cancer cells. Rabusertib (LY2603618) induces bak-dependent apoptosis in AML cell lines.
CHIR-124

CHIR-124 is a novel and potent Chk1 inhibitor with IC50 of 0.3 nM in a cell-free assay. It shows 2,000-fold selectivity against Chk2, 500- to 5,000-fold less activity against CDK2/4 and Cdc2.
MK-8776 (SCH 900776)

MK-8776 (SCH 900776) is a selective Chk1 inhibitor with IC50 of 3 nM in a cell-free assay. It shows 500-fold selectivity against Chk2. Phase 2.
PF-477736

PF-477736 (PF-736, PF-00477736) is a selective, potent and ATP-competitive Chk1 inhibitor with K_i of 0.49 nM in a cell-free assay and also inhibits VEGFR2, Aurora-A, FGFR3, Flt3, Fms (CSF1R), Ret and Yes. It shows ~100-fold selectivity for Chk1 than Chk2. Phase 1.
Y-27632 2HCl

Y-27632 2HCl is a selective ROCK1 (p160ROCK) inhibitor with K_i of 140 nM in a cell-free assay, exhibits >200-fold selectivity over other kinases, including PKC, cAMP-dependent protein kinase, MLCK and PAK.
Palbociclib (PD-0332991) HCl

Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

Features:Non-cytotoxic, and halts cancer cell growth & could be used in glioblastoma that has relapsed after temozolomide treatment (a chemotherapeutic used to treat many cancers).
Alisertib (MLN8237)

Alisertib (MLN8237) is a selective Aurora A inhibitor with IC50 of 1.2 nM in a cell-free assay. It has >200-fold higher selectivity for Aurora A than Aurora B. Alisertib induces cell cycle arrest, apoptosis and autophagy. Phase 3.

Features:First orally available inhibitor of Aurora A.

Choose Your Country or Region

By Signaling Pathways

By product type

AZD7762